IA
AVIR icon

IFP Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

IFP Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22 Hold
4
– – ﹤0.01% 4910
2025
Q4 		$14 Buy
4
+1
+33% +$3 ﹤0.01% 4822
2025
Q3 		$9 Buy
+3
New +$10 ﹤0.01% 4786
2025
Q2 		– Hold
0
– – – 4381
2025
Q1 		– Hold
0
– – – 4014
2024
Q4 		– Hold
0
– – – 4217

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IFP Advisors's AVIR Position: Q1 2026 in Review

IFP Advisors held its Atea Pharmaceuticals (AVIR) position steady in Q1 2026 at 4 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #4910.

IFP Advisors first reported a position in AVIR in Q3 2025 and has held it in 3 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • IFP Advisors held 4 shares of Atea Pharmaceuticals worth $22 as of Q1 2026.
  • IFP Advisors left its Atea Pharmaceuticals share count unchanged in Q1 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #4910 holding.
  • IFP Advisors first reported a position in Atea Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.